IP Library Patent Application 12112924
Patent Application
App. No. 12/112,924

Cardiac Risk Assessment

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/112,924
Abstract

In a system for assessing cardiac risk of a patient, a measuring component measures a cardiac signal comprised of multiple cardiac cycles at multiple periods in time. A processing component calculates sensitivity of cardiac function to sympathetic drive at each of the periods in time from the measured cardiac signal. A risk identification component evaluates a trend of the sensitivity over time as an indicator of a degree of cardiac risk.

Claims (39)

1 . A system for assessing cardiac risk of a patient, the system comprising:

a measuring component that measures a cardiac signal comprised of multiple cardiac cycles at multiple periods in time;

a processing component that calculates sensitivity of cardiac function to sympathetic drive at each of the periods in time from the measured cardiac signal; and

a risk identification component that evaluates a trend of the sensitivity over time as an indicator of a degree of cardiac risk.

2 . The system of claim 1 , wherein the risk identification component evaluates the trend by evaluating a plot of the sensitivity versus time.

3 . The system of claim 1 , wherein the risk identification component evaluates the trend by comparing the trend with a predetermined threshold.

4 . The system of claim 1 , wherein the measuring component, the processing component, and the risk identification component reside in an implantable device.

5 . The system of claim 1 , wherein the measuring component resides in an implantable device, and wherein the processing component and the risk identification component reside in an external device.

6 . The system of claim 5 , further comprising a first telemetry component that resides in the implantable device and a second telemetry component that resides in the external device, wherein the first telemetry component transmits at least a portion of the cardiac signal for receipt by the second telemetry component.

7 . The system of claim 1 , wherein the cardiac function is indicated by an altemans burden over a selected period of time, the alternans burden determined from the cardiac signal.

8 . The system of claim 7 , wherein the alternans burden is a repolarization altemans burden.

9 . The system of claim 7 , wherein the alternans burden is a mechanical altemans burden.

10 . The system of claim 7 , wherein the alternans burden is a QRS altemans burden.

11 . The system of claim 7 , wherein the sensitivity of cardiac function is calculated by computing a ratio of change in the altemans burden to change in a sympathetic tone marker.

12 . The system of claim 7 , wherein the sensitivity of cardiac function is calculated as an onset value of a sympathetic tone marker at which a sustained elevation in the altemans burden appears.

13 . The system of claim 1 , wherein the cardiac function is indicated by a hypertension burden over a selected period of time, the hypertension burden determined from the cardiac signal.

14 . The system of claim 13 wherein the hypertension burden is elevated diastolic blood pressure.

15 . The system of claim 13 wherein the hypertension burden is elevated systolic blood pressure.

16 . The system of claim 1 , wherein sympathetic drive is estimated from a heart rate variability measurement determined from the cardiac signal.

17 . The system of claim 1 , wherein sympathetic drive is estimated from a heart rate increase measurement determined from the cardiac signal.

18 . The system of claim 1 , wherein the cardiac signal is an electrocardiogram signal.

19 . The system of claim 1 , wherein the cardiac signal is an electrogram signal measured using an intracardiac lead.

20 . The system of claim 1 , wherein the cardiac signal is a blood pressure signal.

21 . The system of claim 1 , wherein the cardiac signal is an impedance measurement.

22 . The system of claim 1 , wherein the processing component further calculates a baroreflex sensitivity value from the measured cardiac signal.

23 . The system of claim 22 , wherein an indication of heart rate turbulence, determined from the cardiac signal, indicates the baroreflex sensitivity value.

24 . The system of claim 23 , wherein the indication of heart rate turbulence is a turbulence slope value.

25 . The system of claim 23 , wherein the indication of heart rate turbulence is a turbulence onset value.

26 . The system of claim 1 , wherein the risk identification component adjusts the trend based on circadian variability

27 . The system of claim 1 , wherein the risk identification component filters the trend to remove circadian variability and short term variability.

28 . The system of claim 1 , wherein the trend of the sensitivity over time indicates a degree of cardiac risk that exceeds an expected degree of cardiac risk because of patient non-compliance with a prescribed therapy.

29 . The system of claim 1 , wherein the trend of the sensitivity over time indicates a degree of cardiac risk that exceeds an expected degree of cardiac risk because of insufficient therapy effectiveness.

30 . A method of monitoring effect of a cardiovascular therapy for a patient; the method comprising:

receiving physiologic signal data associated with multiple cardiac cycles;

calculating sensitivity of cardiovascular function to sympathetic drive using the received physiologic signal data;

trending the computed sensitivity over time; and

comparing the sensitivity trend to an expected trend, the expected trend based on a previous condition of the patient and a prescribed therapy regimen that specifies the cardiovascular therapy.

31 . The method of claim 30 , wherein the cardiovascular therapy modulates the effect of the sympathetic tone on cardiac function.

32 . The method of claim 30 , wherein the cardiovascular therapy modulates vascular tone.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2010
From: PARTNERS FOR GROWTH II, L.P.
To: TRANSOMA MEDICAL, INC.
Reel/Frame 024588/0100 →
FORECLOSURE Recorded Mar 23, 2010
From: TRANSOMA MEDICAL, INC.
To: DATA SCIENCES INTERNATIONAL, INC.
Reel/Frame 024120/0696 →
SECURITY AGREEMENT Recorded May 14, 2009
From: TRANSOMA MEDICAL, INC.
To: PARTNERS FOR GROWTH II, L.P.
Reel/Frame 022678/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2009
From: BROCKWAY, MARINA V.; BROCKWAY, BRIAN P.
To: TRANSOMA MEDICAL, INC.
Reel/Frame 022560/0667 →